Clinical Trials
Open
Phase
III
SWOG Clinical Trial Number
CTSU/NRG-BR007
A Phase III Clinical Trial Evaluating De-escalation of Breast Radiation for Conservative Treatment of Stage I, Hormone Sensitive, HER2-Negative, Treatment of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score </= 18 Breast Cancer
Status Notes
CTSU/NRG-BR007 has been endorsed and activated by SWOG, effective 6/15/2021. CTSU/NRG-BR007 was activated by NRG Oncology, effective 6/7/21.
Research Committee(s)
Breast Cancer
Activated
06-07-2021
ClinicalTrials.gov Registry Number
04852887
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2201
A Phase II Study of Neoadjuvant Nivolumab Plus Ipilimumab and Short-Course Radiation in MSI-H/dMMR Locally Advanced Rectal Adenocarcinoma
Status Notes
May Thet Cho, MD SWOG Champion
Research Committee(s)
Gastrointestinal Cancer
Activated
05-13-2021
ClinicalTrials.gov Registry Number
NCT04751370
Open
Phase
III
SWOG Clinical Trial Number
CTSU/A031901
Duration of Immune Checkpoint Therapy in Locally Advanced or Metastatic Urothelial Carcinoma: A Randomized Phase 3 Non-Inferiority Trial
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04637594
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA8185
Phase II Study of Bladder-SparIng ChemoradiatioN with MEDI4736 (Durvalumab) in Clinical Stage III, Node PosItive BladdeR CancEr (INSPIRE)
Status Notes
SWOG is participating in this study through the Cancer Trials Support Unit (CTSU) of the National Cancer Institute.
Research Committee(s)
Genitourinary Cancer
Activated
05-01-2021
ClinicalTrials.gov Registry Number
NCT04216290
Open
Phase
II
SWOG Clinical Trial Number
CTSU/EA2192
APOLLO: A Randomized Phase II Double-Blind Study of Olaparib Versus Placebo Following Adjuvant Chemotherapy in Patients with Resected Pancreatic Cancer and a Pathogenic BRCA1, BRCA2 or PALB2 Mutation
Research Committee(s)
Gastrointestinal Cancer
Activated
04-29-2021
ClinicalTrials.gov Registry Number
NCT04858334
Open
Phase
II
Accrual
14%
SWOG Clinical Trial Number
S1900E
A PHASE II STUDY OF AMG 510 IN PATIENTS WITH PREVIOUSLY TREATED STAGE IV OR RECURRENT KRAS G12C MUTATED NON-SQUAMOUS NON-SMALL CELL LUNG CANCER (ECOG-ACRIN LUNG-MAP SUB-STUDY)
Status Notes
S1900E will open to accrual April 2, 2021, effective 12:00 pm PST.
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
This is an FDA registration study. There will be additional centralized and on-site monitoring conducted in addition to routine audits. Sites must also maintain a study specific Trial Master File for this study (https://swog.org/Visitors/QA/Index.asp).
Research Committee(s)
LungMAP
Lung Cancer
Activated
04-02-2021